Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production

Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637 · see citing works

CTLA-4 can function as a negative regulator of T cell activation

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · see citing works

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206 · see citing works

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857 · see citing works

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786 · see citing works

A Theory of Self-Nonself Discrimination

Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755 · see citing works

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · see citing works

A new member of the immunoglobulin superfamily—CTLA-4

Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307 · see citing works

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Linsley, P. S., Brady, W., Grosmaire, L. S., Aruffo, A. A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.721 · Cited by 1,126 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 977 · see citing works

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923 · see citing works

T-cell regulation by CD28 and CTLA-4

Alegre, M., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature reviews. Immunology · doi:10.1038/35105024 · Cited by 912 · see citing works

CD4+CD25+ T Cells Inhibit Both the Induction and Effector Function of Autoreactive T Cells and Represent a Unique Lineage of Immunoregulatory Cells

Suri‐Payer, E., Amar, A. Z., Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1212 · Cited by 858 · see citing works

CTLA-4 ligation blocks CD28-dependent T cell activation.

Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2541 · Cited by 801 · see citing works

Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation

Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., & Young, H. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3596 · Cited by 742 · see citing works

Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation

Woo, E. Y., Yeh, H., Chu, C., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 689 · see citing works

Effect of interleukin‐10 on dendritic cell maturation and function

Smedt, T. D., van Mechelen, M., Becker, G. D., Urbain, J., Léo, O., & Moser, M. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270526 · Cited by 564 · see citing works

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 427 · see citing works

CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation

Brunner-Weinzierl, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419 · see citing works

Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)

Chen, J., Sun, Y., & Nabel, G. J. (1998) · Science · doi:10.1126/science.282.5394.1714 · Cited by 379 · see citing works

Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation

Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Trapani, G. D., Clarke, F. M., Sitia, R., & Rubartelli, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022630299 · Cited by 372 · see citing works

Characterization of CTLA-4 structure and expression on human T cells.

Lindsten, T., Lee, K. P., Harris, E. S., Petryniak, B., Craighead, N., Reynolds, P. J., Lombard, D. B., Freeman, G. J., Nadler, L. M., Gray, G. S., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3489 · Cited by 316 · see citing works

Identification and distribution of the costimulatory receptor CD28 in the mouse

Gross, J. A., Callas, E., & Allison, J. P. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.2.380 · Cited by 310 · see citing works

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J. L., Villaseñor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 308 · see citing works

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes

Lühder, F., Höglund, P., Allison, J. P., Benoist, C. O., & Mathis, D. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.427 · Cited by 290 · see citing works

Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40‐ligand) and TNF‐α, but strongly enhanced by interleukin‐10

Ludewig, B., Graf, D., Gelderblom, H., Becker, Y., Kroczek, R., & Pauli, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250722 · Cited by 267 · see citing works

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis

Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H., & Racke, M. K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1333 · Cited by 226 · see citing works

Functional Analysis of Antigen-Specific T Lymphocytes by Serial Measurement of Gene Expression in Peripheral Blood Mononuclear Cells and Tumor Specimens

Kammula, U. S., Lee, K.-H., Riker, A. I., Wang, E., Ohnmacht, G. A., Rosenberg, S. A., & Marincola, F. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6867 · Cited by 195 · see citing works

Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice.

Fontana, A., Frei, K., Bodmer, S., Hofer, E., Schreier, M. H., Palladino, M. A., & Zinkernagel, R. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3230 · Cited by 160 · see citing works

Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches

Spahn, T. W., Fontana, A., Faria, A. M. C., Slavin, A., Eugster, H., Zhang, X., Koni, P. A., Ruddle, N. H., Flavell, R. A., Rennert, P. D., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200104)31:4 · Cited by 143 · see citing works

Potential role of IL-8, platelet-activating factor and TNF-α in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis

Drost, E., & MacNee, W. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200202)32:2 · Cited by 135 · see citing works

Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens

Phan, G. Q., Touloukian, C. E., Yang, J. C.-H., Restifo, N. P., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Seipp, C. A., Rogers-Freezer, L. J., et al. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00007 · Cited by 112 · see citing works

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Ha, P., Schwarz, S. L., Wunderlich, J. R., & Rosenberg, S. A. (1998) · PubMed · Cited by 110 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

N aturally A rising CD4+R egulatory T C ells for I mmunologic S elf -T olerance and N egative C ontrol of I mmune R esponses

Sakaguchi, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,293 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works

Immune Checkpoint Blockade in Cancer Therapy

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Regulatory T cells, tumour immunity and immunotherapy

Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,075 · see citing works

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works

Non-small cell lung cancer: current treatment and future advances

Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944 · see citing works

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · see citing works

Regulatory T cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · see citing works

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Rosenberg, S. A., Restifo, N. P., Yang, J. C.-H., Morgan, R. A., & Dudley, M. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2355 · Cited by 1,654 · see citing works

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625 · see citing works

Cytokines in cancer pathogenesis and cancer therapy

Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,567 · see citing works

Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease

Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z. T., Shimizu, J., Takahashi, T., & Nomura, T. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00427.x · Cited by 1,548 · see citing works

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

The fundamental basis of inflammatory bowel disease

Strober, W., Fuss, I. J., & Mannon, P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30587 · Cited by 1,310 · see citing works

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,257 · see citing works

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works

Cancer immunotherapy: the beginning of the end of cancer?

Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,192 · see citing works

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · see citing works

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 1,151 · see citing works

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115 · see citing works

A2A adenosine receptor protects tumors from antitumor T cells

Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,066 · see citing works

Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,016 · see citing works

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · see citing works

Kinase inhibitors: the road ahead

Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · see citing works

Neoadjuvant checkpoint blockade for cancer immunotherapy

Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

Dendritic cell immunotherapy: mapping the way

Figdor, C. G., de Vries, I. J. M., Lesterhuis, W. J., & Melief, C. J. M. (2004) · Nature Medicine · doi:10.1038/nm1039 · Cited by 940 · see citing works

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 854 · see citing works

Regulatory T cells: how do they suppress immune responses?

Sakaguchi, S., Wing, K., Onishi, Y., Martín, P. P., & Yamaguchi, T. (2009) · International Immunology · doi:10.1093/intimm/dxp095 · Cited by 850 · see citing works

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · see citing works

Cancer Immunology

Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 782 · see citing works

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease

Szabo, P. A., Levitin, H. M., Miron, M., Snyder, M. E., Senda, T., Yuan, J., Cheng, Y. L., Bush, E. C., Dogra, P., Thapa, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12464-3 · Cited by 756 · see citing works

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · see citing works

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works

Mechanisms of Immune Evasion by Tumors

Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 690 · see citing works

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 689 · see citing works

Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.

Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · see citing works

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655 · see citing works

Adoptive-cell-transfer therapy for the treatment of patients with cancer

Dudley, M. E., & Rosenberg, S. A. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1167 · Cited by 653 · see citing works

HUMAN T CELL RESPONSES AGAINST MELANOMA

Boon, T., Coulie, P. G., den Eynde, B. J. V., & van der Bruggen, P. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651 · see citing works

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 633 · see citing works

Immunostimulatory monoclonal antibodies for cancer therapy

Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 626 · see citing works

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625 · see citing works

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works

Cancer Immunotherapy: A Treatment for the Masses

Blattman, J. N., & Greenberg, P. D. (2004) · Science · doi:10.1126/science.1100369 · Cited by 608 · see citing works

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · see citing works

Cancer Immunotherapy Comes of Age

Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 591 · see citing works

Checkpoint Blockade in Cancer Immunotherapy

Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 577 · see citing works

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Apétoh, L., Ghiringhelli, F., Tesnière, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J. P., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 575 · see citing works

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 569 · see citing works

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566 · see citing works

Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon

Gogas, H. J., Ioannovich, J. D., Dafni, U. G., Stauropoulou-Giokas, C., Frangia, K. B., Tsoutsos, D. A., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 565 · see citing works

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Puzanov, I. J., Milhem, M. M., Minor, D. R., Hamid, O., Ai, L., Chen, L., Chastain, M. A., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 564 · see citing works

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Korman, A. J., Garrett-Thomson, S. C., & Lönberg, N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 561 · see citing works

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A. L., Alumkal, J. J., Scher, H. I., Chin, K. M., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 556 · see citing works

CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · see citing works

Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients

van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., van der Veen, J. P. W., Bos, J. D., Melief, C. J. M., Vyth‐Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 540 · see citing works

When worlds collide: Th17 and Treg cells in cancer and autoimmunity

Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular &amp; Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535 · see citing works

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection

Rubinstein, N., Alvarez, M. J., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 529 · see citing works

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

Kaufmann, D., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M. A., Rathod, A., Trocha, A. K., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 522 · see citing works

Prognostic significance of autoimmunity during treatment of melanoma with interferon

Krauze, M. T., Tarhini, A. A., Gogas, H. J., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507 · see citing works

Cancer Immunotherapy by Dendritic Cells

Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 505 · see citing works

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy

Giles, A. J., Hutchinson, M.-K. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0371-5 · Cited by 498 · see citing works

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492 · see citing works

Immune checkpoint inhibitor–related dermatologic adverse events

Geisler, A. N., Phillips, G. S., M.S, D. M. B., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 490 · see citing works

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477 · see citing works

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 477 · see citing works

Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation

Ízcue, A., Coombes, J. L., & Powrie, F. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00423.x · Cited by 473 · see citing works

Immune Checkpoint Inhibitors: Basics and Challenges

Li, B., Chan, H. L., & Chen, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 473 · see citing works

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy

Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 467 · see citing works

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells

Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 465 · see citing works

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · see citing works

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460 · see citing works

Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460 · see citing works

Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Chandra, A., Pius, C., Nabeel, M., Nair, M. P., Vishwanatha, J. K., Ahmad, S., & Basha, R. M. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 455 · see citing works

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

Ritchie, D. S., Neeson, P. J., Khot, A. S., Peinert, S., Tai, T. Y., Tainton, K. M., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 442 · see citing works

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 439 · see citing works

Immune resistance orchestrated by the tumor microenvironment

Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437 · see citing works

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · see citing works

Human antibodies from transgenic animals.

Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434 · see citing works

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Sanderson, K. M., Scotland, R., Lee, P. P., Liu, D., Groshen, S. G., Snively, J., Sian, S., Nichol, G. M., Davis, T. A., Keler, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 432 · see citing works

Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 418 · see citing works

DNA vaccines: precision tools for activating effective immunity against cancer

Rice, J., Ottensmeier, C. H. H., & Stevenson, F. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2326 · Cited by 412 · see citing works

A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L. H., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 404 · see citing works

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403 · see citing works

Overcoming immunological tolerance to melanoma: targeting CTLA-4

HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36 · see citing works

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492 · see citing works

CTLA‐4 to overcome immunological tolerance to melanoma

Hodi, F. S. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01383.x

Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma

Robinson, M. R., Chan, C. C., Yang, J. C.-H., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159 · see citing works

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

Blansfield, J., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C. L., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 352 · see citing works